A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy The proportion of patients achieving a PSA decline of >50% (PSA response) according to Prostate-Specific Antigen Working Group (PSAWG) criteria

• Country None
• organs None
• Specialty None

A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy To evaluate the safety, tolerability and recommended dose of abiraterone acetate administered orally, by continuous once-daily administration in patients with HRPC. To determine the effect of abirat...

• Country None
• organs None
• Specialty None

A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy To evaluate the anti-tumor effects of CB7630 in patients with androgen independent metastatic prostate cancer (AIPC) who have failed docetaxel based chemotherapy, as measured by the proportion of pati...

• Country None
• organs None
• Specialty None